Planar cell polarity pathway and development of the human visual cortex

Jean Shin[1,2], Shaojie Ma[3], Edith Hofer[4,5], Yash Patel[2], Gennady V. Roshchupkin[6,7], André M. Sousa[8], Xueqiu Jian[9], Rebecca F Gottesman[10], Thomas H Mosley[11], Myriam Fornage[9], Yasaman Saba[12], Lukas Pirpamer[3,4], Reinhold Schmidt[3,4], Helena Schmidt[12], Bernard Mazoyer[13], Amaia Carrion-Castillo[14], Joshua C Bis[15], Shuo Li[16], Qiong Yang[16], Michelle Luciano[17,18], Sherif Karama[19], Lindsay Lewis[19], Mark E Bastin[17,20], Matthew A Harris[20], Ian J. Deary[17,18], Joanna M. Wardlaw[17,20,21], Markus Scholz[22,23], Markus Loeffler[22,23], Veronica Witte[24,25], Frauke Beyer[24,25], Arno Villringer[24,26], Hieab H.H.H. Adams[6,7], M. Arfan Ikram[6,7,27], William S Kremen[28], Nathan A Gillespie[29], the ENIGMA Consortium, Nenad Sestan[3], Zdenka Pausova[1], Sudha Seshadri[30,31], Tomas Paus[2,32]; for the neuroCHARGE Working Group

[1]The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada;
[2]Holland Bloorview Kids Rehabilitation Hospital, Bloorview Research Institute, University of Toronto, Toronto, ON, Canada;
[3]Departments of Genetics and Neuroscience, Yale University School of Medicine, New Haven, CT, USA;
[4]Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Austria;
[5]Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria;
[6]Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands;
[7]Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands;
[8]Department of Neuroscience and Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT, USA;
[9]Institute of Molecular Medicine, McGovern Medical School at The University of Texas Health Science Center at Houston, USA;
[10]Johns Hopkins School of Medicine, Baltimore, MD, USA;
[11]University of Mississippi, Jackson, MS, USA;
[12]Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, Austria;
[13]Groupe d'Imagerie Neurofonctionnelle, Institut des Maladies Neurodégénératives, Centre National de la Recherche Scientifique, Commissariat à l'Energie Atomique, et Université de Bordeaux, Bordeaux, France;
[14]Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands;
[15]Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA;
[16]Department of Biostatistics, Boston University School of Public Health, MA, USA;
[17]Centre for Cognitive Epidemiology and Cognitive Ageing, University of Edinburgh, Edinburgh, UK;
[18]Department of Psychology, University of Edinburgh, Edinburgh, UK;
[19]Montreal Neurological Institute, McGill University, Montreal, QC, Canada;
[20]Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK;
[21]UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK;
[22]University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany;
[23]LIFE Research Center for Civilization Diseases, Leipzig, Germany;
[24]Department of Neurology, Max Planck Institute for Human Cognitive and Brain

Sciences, Leipzig, Germany;
[25]Faculty of Medicine, CRC 1052 Obesity Mechanisms, University of Leipzig, Leipzig, Germany;
[26]Day Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany;
[27]Department of Neurology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands;
[28]Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA;
[29]Virginia Institute for Psychiatric and Behavioural Genetics, Virginia Commonwealth University, Richmond, VA, USA;
[30]Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, TX, USA;
[31]Department of Neurology, Boston University School of Medicine, MA, USA;
[32]Departments of Psychology and Psychiatry, University of Toronto Toronto, ON, Canada.

The radial unit hypothesis provides a framework for global (proliferation) and regional (distribution) expansion of the primate cerebral cortex[1]. Using principal component analysis (PCA), we have identified cortical regions with shared variance in their surface area and cortical thickness, respectively, segmented from magnetic resonance images obtained in 19,171 participants. We then carried out meta-analyses of genome-wide association studies of the first two principal components for each phenotype. For surface area (but not cortical thickness), we have detected strong associations between each of the components and single nucleotide polymorphisms in a number of gene loci. The first ("global") component was associated mainly with loci on chromosome 17 ($8.8 \times 10^{-26} \leq p \leq 2.3 \times 10^{-14}$), including those detected previously as linked with intracranial volume[2,3]. The second (regional) component captured shared variation in the surface area of the primary and adjacent secondary visual cortices and showed a robust association with polymorphisms in *a* locus on chromosome 14 containing *Disheveled Associated Activator of Morphogenesis 1* (*DAAM1*; $p=3.0 \times 10^{-32}$). *DAAM1* is a key component in the planar-cell-polarity signaling pathway[4,5]. In follow-up studies, we have focused on the latter finding and established that: (1) *DAAM1* is highly expressed between 12th and 22nd post-conception weeks in the human cerebral cortex; (2) genes co-expressed with *DAAM1* in the primary visual cortex are enriched in mitochondria-related pathways; and (3) volume of the lateral geniculate nucleus, which projects to regions of the visual cortex staining for cytochrome oxidase (a mitochondrial enzyme), correlates with the surface area of the visual cortex in major-allele homozygotes but not in carriers of the minor allele. Altogether, we speculate that - in concert with thalamocortical input to cortical subplate - *DAAM1* enables migration of neurons to cytochrome-oxidase rich regions of the visual cortex, and, in turn, facilitates regional expansion of this set of cortical regions during development.

Using magnetic resonance imaging, one can derive a number of metrics informative with regard to development and aging of the human cerebral cortex, including cortical surface area and cortical thickness. The two measures provide insights into different developmental processes, each with a different timeline. Cortical surface area reflects primarily the tangential growth of the cerebral cortex during prenatal development; the phase of *symmetric division of progenitor cells* in the proliferative zones during the first trimester is particularly important for the tangential growth through additions of ontogenetic columns[1]. The subsequent phase of *asymmetric division* continues to increase the number of ontogenetic columns (and thus surface area) but it also begins to

contribute to the <u>thickness of cerebral cortex</u> formed by post-mitotic neurons migrating from the proliferative zones to the cortical plate in the inside-out manner[1]. Ionizing radiation of the (monkey) fetus during early gestation reduces surface area (sparing cortical thickness) while the same radiation applied in midgestation affects both the surface area and cortical thickness[6]. While surface area remains stable after early childhood, cortical thickness continues to change, in particular during puberty and aging. Furthermore, both surface area and cortical thickness vary across individuals in global and regional manner.

Here we report findings obtained in 19,171 participants assessed across 13 cohorts from the CHARGE Consortium and the UK Biobank (Table E1 in Extended Data). To identify genetic loci associated with global and regional variations in each cortical phenotype, i.e., the surface area and thickness of the cerebral cortex, we have first carried out principal component analysis of regional values (34 regions segmented by FreeSurfer) in each cohort. For each phenotype, the first (PC1) and second (PC2) components loaded in similar sets of cortical regions across all 13 cohorts (Figures E1 [surface area] and E2 [cortical thickness] in Extended Data). Figure 1 illustrates the loadings for each of the 34 cortical regions in PC1 (Fig. 1A) and PC2 (Fig. 1B) for surface area. Note that PC2 includes only a handful of cortical regions in the medial aspect of the occipital lobe, including the pericalcarine (primary visual) cortex.

Figure 1. Lateral and medial views of median principal component (PC) loadings for the surface area of the 34 cortical regions in CHARGE consortium cohorts. Lateral (left column) and medial (right column) views of the median PC loadings are shown for PC1 (top) and PC2 (bottom). Each cohort estimated the surface area of the 34 cortical regions (left and right hemispheres summed), using FreeSurfer and carried out unrotated principal component analyses to obtain PC1 and PC2 loadings. Then, for each cortical region, median value of loadings was obtained across the cohorts. The red-to-blue color indicates the positive-to-negative loading values (i.e., correlation between PC scores and raw data) as indicated by the color bar. The median loading values were then used to derive the 'general' PC score for each individual and later used as the response variable in the GWAS meta-analyses.

We then executed a genome-wide association analysis (GWAS) in each of the 13 cohorts and, subsequently, meta-analyzed these cohort-based results (Supplementary Information) for each of the four phenotypes, namely PC1 and PC2 of surface area, and PC1 and PC2 of cortical thickness. For surface area, the first ("global") component was associated mainly with a number of loci on chromosome 17, including those detected previously as linked with intracranial volume[2,3] (Figure E3A and Table E2A in Extended Data). The second ("regional") component was associated mainly with a locus on chromosome 14 containing *DAAM1* (Figure 2, Figures E3B and E4, and Table E2B in Extended Data). For cortical thickness, meta-GWAS revealed a single locus associated with PC1 and a single locus associated with PC2 (Figure E5). The *DAAM1* locus (top hit: rs73313052) was associated with surface area (but not cortical thickness) of each of the four cortical regions loading on PC2 when examined on a region-by-region basis, as reported in the two companion reports from the CHARGE and ENIGMA Consortia (Table E3 in Extended Data).

Figure2. Regional association plot for rs73313052, the top PC2 single nucleotide polymorphism (SNP). Each point indicates a SNP tested in the meta genome-wide association study (GWAS) of surface area PC2 within the shown genomic region. The top PC2 SNP is indicated by the purple diamond. The x-axis represents the genomic position on the human chromosome 14 (hg19). The left-vertical axis indicates the $-\log_{10}P$ values obtained from the GWAS meta-analysis (on the left side); and the right-axis, the estimated recombination rate from HapMap samples. The red-to-blue colors indicate the degree of linkage disequilibrium (LD) between each SNP and rs73313052. The LD was based on the pairwise squared allelic correlation r^2 estimated using the 1000 Genomes European reference panels (Nov 2014 EUR). The plot was created using LocusZoom (http://locuszoom.org/).

DAAM1 is a key component of the planar-cell-polarity signaling pathway[4,5]; it acts as a bridging factor between Disheveled, Rho-family GTPases and Rho-associated kinases[7], a molecular complex involved in organizing actin cytoskeleton[8].

In order to gain insights into possible mechanisms by which *DAAM1* contributes to the tangential expansion of the human visual cortex, we have carried out a number of follow-up studies. **First**, we examined *DAAM1* expression in the human brain using the BrainSpan dataset (Table E4 in Extended Data). *DAAM1* is expressed in the cerebral cortex between ~80 and ~150 post-conception days (280-day gestation); after birth, its expression is very low (Fig. 3, Table E4). Note that, in monkeys, neurogenesis of the primary visual cortex begins around embryonic day 40 (E40) and ends at E100 (165-day gestation)[1].

Figure 3. Spatial and temporal expression of *DAAM1* on BrainSpan mRNA-seq data. The mRNA expression levels were measured by RNA sequencing in 607 brain tissues from 18 female and 23 male donors available in BrainSpan database (http://www.brainspan.org/). For a given brain structure, *DAAM1* expression value was averaged and then fitted across differentiation windows using spline function implemented in MATLAB to get smooth *DAAM1* expression dynamics. Each colored band represents the fitted expression levels in RPKM (reads per kilobase per million) of *DAAM1*. Brain structure includes 11 cortical and 5 sub-cortical regions: dorsolateral prefrontal cortex (DFC), ventrolateral prefrontal cortex (VFC), medial frontal cortex (MFC), orbitofrontal cortex (OFC), primary motor cortex (M1C), primary sensory cortex (S1C), inferior parietal cortex (IPC), primary auditory cortex (A1C), superior temporal cortex (STC), inferior temporal cortex (ITC), primary visual cortex (V1C), hippocampus (HIP), amygdala (AMY), striatum (STR), mediodorsal nucleus of thalamus (MD) and cerebellar cortex (CBC). The human brain differentiation was split into 9 windows based on post conception days: 52-69 (Window 1), 70-111 (Window 2), 112-132 (Window 3), 133-167 (Window 4), 168-447 (Window5), 448 - 1299 (Window 6), 1300-4648 (Window 7), 4649-7570 (Window 8), and 7571-14876 (Window 8). The red line indicates the boundary between pre- and postnatal periods. The pink panel indicates the

time where *DAAM1* has peak expression in V1C. Blue-to-yellow colors represent low-to-high expression levels of *DAAM1* as indicated in the color bar.

Second, we examined co-expression of *DAAM1* across all cortical regions and prenatal time points using the same BrainSpan dataset. As expression of *DAAM1* increases and decreases, so does expression of genes enriched in pathways involving neuron migration and cytoskeleton organization, among others (Table E5A in Extended Data). On the other hand, expression of a large number of genes varies in the direction opposite to that of *DAAM1*, including genes enriched in pathways involved in a number of metabolic processes (Table E5B in Extended Data). To ascertain the pattern of *DAAM1* co-expression *specific* to the primary visual cortex (V1), we have identified genes co-expressed highly (top 1%) in V1 but not in any other cortical region (i.e., not present among top 1% in any of the other eight regions). This analysis yielded striking enrichment for mitochondria-related genes co-expressed strongly in the same direction as *DAAM1* in V1 but not in the other cortical regions (Table E6 in Extended Data). This observation turned our attention to the well-known parcellation of the visual cortex to cytochrome-oxidase rich sub-regions, so-called "blobs" (V1) and "stripes" (V2/V3)[9]. We then examined co-localization of *DAAM1* and a mitochondrial marker ATP5A in the developing (22nd post-conception week) visual cortex (Figure E6); its co-localization is consistent with the co-expression analyses described above. It is known that post-mitotic neurons migrate, along radial glia, from proliferative (ventricular and subventricular) zones to subplate zones, which contain afferents from the thalamic radiation[1]. Activity carried by these afferents from the retina is critical for the development of the primate visual cortex; enucleation of the eyes during fetal development results in the reduction of the surface area (but not thickness) of the monkey primary visual cortex[10,11], as well as in a reduced size of the lateral geniculate nucleus (LGN)[11]. A tight relationship exists between the volume of LGN and surface area of the primary visual cortex in the human (adult) brain[12]. Furthermore, the koniocellular portion of LGN (which carries signals from short wavelength [blue] cones) appears to project specifically to cytochrome-oxidase rich areas of the visual cortex[13]. Therefore, we hypothesized that DAAM1 contributes to the migration of cytochrome-oxidase positive neurons in response to the LGN inputs in the subplate zones during fetal development. **Third**, to test this hypothesis in our data, we predicted that the expected relationship between the LGN volume (a proxy for retinal inputs during fetal development) and V1 surface area will be present only in *DAAM1* (rs73313052) major-allele homozygotes (GG) but not in the carriers of minor allele (GA or AA). This prediction was confirmed: an interaction between rs73313052 genotype and LGN volume vis-à-vis PC2 magnitude was significant when examined in a cohort with available LGN volumes (GG: r=0.13, p=0.0006, n=694; A carriers: r=-0.06, p=0.37, n=206; interaction: t ratio= -2.47, p=0.014, n=900; Figure E7 in Extended Data).

Finally, to examine similarities between the molecular architecture underlying global (PC1) and regional (PC2) expansion of the cortical surface area and that of other complex traits, we have calculated genetic correlations between these two brain phenotypes and a number of psychiatric disorders, personality characteristics, general cognitive function and educational attainment (Figures E8 through E20 in Extended Data). We find strong genetic correlations between the tangential growth of cerebral cortex and three behavioural traits, namely general cognitive function, educational attainment and schizophrenia (Figure 4). This shared molecular architecture is consistent with the importance of early cortical development for both normal[14] and abnormal cognitive functioning later in life.

Figure
cognit
PC2 results are presented in the left and right columns, respectively. For this pleiotropy analysis, we examined whether there are any genetic loci associated with both surface area PC (e.g., PC1) *and* a given phenotype (e.g., global cognitive function), using GWAS summary statistics of the SNPs tested in both GWAS. The statistical significance was assessed by comparing the sum of the ranks of the observed pair of p-values (from the two GWAS) against the null distribution of the sum of ranks of p-values generated from the uniform distributions. The information on the sources of the GWAS results and pleiotropy analysis method used for obtaining the displayed results is presented in Extended Data Figures (Figures E8, E18 and E19).

In summary, we discovered a non-overlapping set of 74 'independent' single nucleotide polymorphisms within 22 genomic loci contributing to the global and regional tangential growth (surface area) of the human cerebral cortex (Table E7, in Extended Data). On the other hand, our meta-GWAS of cortical thickness, carried out in the same individuals, yielded only two loci. This negative finding is consistent with a very low number of loci associated with both global and regional values of cortical thickness reported in the two companion reports from the CHARGE and ENIGMA Consortia; it may reflect substantial dynamics of cortical thickness during puberty[15] and aging[16]. Through a series of follow-up studies, we formulated a working model by which *DAAM1* regulates tangential expansion of the visual cortex by interacting with LGN inputs, likely at the level of cortical subplate, during mid-gestation. This finding illustrates how specification of cortical areas, and their relative growth, might be guided by an interaction between fetal environment and generic developmental mechanisms, such as those constituting planar-cell-polarity signaling pathway.

References

1. Rakic P. Specification of cerebral cortical areas. *Science.* Jul 8 1988;241(4862):170-176.

2. Adams HH, Hibar DP, Chouraki V, et al. Novel genetic loci underlying human intracranial volume identified through genome-wide association. *Nat Neurosci.* Oct 03 2016.

3. Hibar DP, Stein JL, Renteria ME, et al. Common genetic variants influence human subcortical brain structures. *Nature.* Apr 9 2015;520(7546):224-229.

4. Tissir F, Goffinet AM. Planar cell polarity signaling in neural development. *Curr Opin Neurobiol.* Oct 2010;20(5):572-577.

5. Beane WS, Tseng AS, Morokuma J, Lemire JM, Levin M. Inhibition of planar cell polarity extends neural growth during regeneration, homeostasis, and development. *Stem cells and development.* Aug 10 2012;21(12):2085-2094.

6. Selemon LD, Ceritoglu C, Ratnanather JT, et al. Distinct abnormalities of the primate prefrontal cortex caused by ionizing radiation in early or midgestation. *J Comp Neurol.* Apr 1 2013;521(5):1040-1053.

7. Habas R, Kato Y, He X. Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. *Cell.* Dec 28 2001;107(7):843-854.

8. Yang Y, Mlodzik M. Wnt-Frizzled/planar cell polarity signaling: cellular orientation by facing the wind (Wnt). *Annual review of cell and developmental biology.* 2015;31:623-646.

9. Livingstone MS, Hubel DH. Thalamic inputs to cytochrome oxidase-rich regions in monkey visual cortex. *Proc Natl Acad Sci U S A.* Oct 1982;79(19):6098-6101.

10. Bourgeois JP, Rakic P. Synaptogenesis in the occipital cortex of macaque monkey devoid of retinal input from early embryonic stages. *Eur J Neurosci.* May 1996;8(5):942-950.

11. Dehay C, Giroud P, Berland M, Killackey H, Kennedy H. Contribution of thalamic input to the specification of cytoarchitectonic cortical fields in the primate: effects of bilateral enucleation in the fetal monkey on the boundaries, dimensions, and gyrification of striate and extrastriate cortex. *J Comp Neurol.* Mar 25 1996;367(1):70-89.

12. Andrews TJ, Halpern SD, Purves D. Correlated size variations in human visual cortex, lateral geniculate nucleus, and optic tract. *J Neurosci.* Apr 15 1997;17(8):2859-2868.

13. Hendry SH, Reid RC. The koniocellular pathway in primate vision. *Annu Rev Neurosci.* 2000;23:127-153.

14. Vuoksimaa E, Panizzon MS, Chen CH, et al. The Genetic Association Between Neocortical Volume and General Cognitive Ability Is Driven by Global Surface Area Rather Than Thickness. *Cereb Cortex.* Aug 2015;25(8):2127-2137.

15. Walhovd KB, Fjell AM, Giedd J, Dale AM, Brown TT. Through Thick and Thin: a Need to Reconcile Contradictory Results on Trajectories in Human Cortical Development. *Cereb Cortex.* Feb 01 2017;27(2):1472-1481.

16. Vinke EJ, de Groot M, Venkatraghavan V, et al. Trajectories of imaging markers in brain aging: the Rotterdam Study. *Neurobiol Aging.* Jul 17 2018;71:32-40.

ACKNOWLEDGMENTS

ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

The Austrian Stroke Prevention Study (ASPS): The authors thank the staff and the participants for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment, Elfi Hofer for the technical assistance at creating the DNA bank, Ing. Johann Semmler and Anita Harb for DNA sequencing and DNA analyses by TaqMan assays and Irmgard Poelzl for supervising the quality management processes after ISO9001 at the biobanking and DNA analyses. The research reported in this article was funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180 and supported by the Austrian National Bank Anniversary Fund, P15435, the Austrian Ministry of Science under the aegis of the EU Joint Programme-Neurodegenerative Disease Research (JPND)-www.jpnd.eu and by the Austrian Science Fund P20545-B05. The Medical University of Graz supports the databank of the ASPS.

BIL&GIN: Funded in part by InterLabex 2013 grant from the Bordeaux Initiative of Excellence (ANR grant No.–10–IDEX-03-02), by Netherlands Organization for Scientific Research (NWO, grant No. 054-15-101), and French National Research Agency (ANR, grant No. 15-HBPR-0001-03) as part of the FLAG-ERA consortium project 'MULTI-LATERAL', a Partner Project to the European Union's Flagship Human Brain Project.

Cardiovascular Health Study (CHS): This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC15103, and HHSN268200960009C; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and R01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, N01HC15103, and R01AG20098 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Framingham Heart Study (FHS): The Framingham Heart Study is supported by the National Heart, Lung and Blood Institute (NHLBI) Framingham Heart Study (contracts N01-HC-25195 and HHSN268201500001I), the Boston University School of Medicine, and by grants from the National Institute of Health (AG054076, AG033193, AG049505, AG033040, NS017950, AG049607). We would like to thank the dedication of the Framingham Study participant. We also thank the Framingham study team, especially the Neurology core, both investigators and staff, for their contributions to data collection.

LIFE-Adult: The LIFE-Adult was funded by the Leipzig Research Center for Civilization Diseases (LIFE). LIFE is an organizational unit affiliated to the Medical Faculty of the University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initiative (Grant Numbers: 713-241202, 713-241202, 14505/2470, 14575/2470). Analysis was also funded by the Deutsche Forschungsgemeinschaft (Grant Number: CRC 1052 "Obesity mechanisms" A1). We thank the participants of LIFE-Adult very much for their time and blood samples. We thank Kerstin Wirkner very much for running the LIFE study center and Ralph Burkhardt for genotyping.

Rotterdam Study (RS): The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) were executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. This work has been performed as part of the CoSTREAM project (www.costream.eu) and has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667375. This project has also received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (project: ORACLE, grant agreement No: 678543).

We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, and Carolina Medina-Gomez, for their help in creating the GWAS database, and Karol Estrada, Yurii Aulchenko, and Carolina Medina-Gomez, for the creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.

Saguenay Youth Study (SYS): The Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada fund the SYS. Computations were performed on the GPC supercomputer at the SciNet HPC Consortium. SciNet is funded by: the Canada Foundation for Innovation under the auspices of Compute Canada; the Government of Ontario; Ontario Research Fund - Research Excellence; and the University of Toronto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

UK Biobank: This research has been conducted using the UK Biobank Resource under Application Number ' 23509'.

ENIGMA Consortium: Katrina L. Grasby (Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia), Neda Jahanshad (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Jodie N. Painter (Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia), Lucía Colodro-Conde (Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia), Janita Bralten (Department of Human Genetics, Radboud university

medical center, Nijmegen, The Netherlands), Derrek P. Hibar (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Penelope A. Lind (Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia), Fabrizio Pizzagalli (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Christopher R.K. Ching (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Mary Agnes B. McMahon (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Natalia Shatokhina (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Leo C.P. Zsembik (Department of Genetics & UNC Neuroscience Center, University of North Carolina at Chapel HIll, Chapel Hill, USA), Ingrid Agartz (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Saud Alhusaini (Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland), Marcio A.A. Almeida (Department of Human Genetics and South Texas Diabetes and Obesity Institute, Rio Grande Valley School of Medicine, University of Texas, Brownsville, USA), Dag Alnæs (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Inge K. Amlien (Centre for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Oslo, Norway), Micael Andersson (Department of Integrative Medical Biology, Umeå University, Umeå, Sweden), Tyler Ard (Laboratory of Neuro Imaging, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, USA), Nicola J. Armstrong (Mathematics and Statistics, Murdoch University, Murdoch, Australia), Allison Ashley-Koch (Duke Molecular Physiology Institute, Duke University Medical Center, Durham, USA), Manon Bernard (The Hospital for Sick Children, University of Toronto, Toronto, Canada), Rachel M. Brouwer (Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Elizabeth E.L. Buimer (Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Robin Bülow (Institute of Diagnostic Radiology and Neuroradiology, University Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany), Christian Bürger (Department of Psychiatry, University of Münster, Münster, Germany), Dara M. Cannon (Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway, Galway, Ireland), Mallar Chakravarty (Douglas Mental Health University Institute, McGill University, Montreal, Canada), Qiang Chen (Lieber Institute for Brain Development, Baltimore, USA), Joshua W. Cheung (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Baptiste Couvy-Duchesne (Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia), Anders M. Dale (Department of Neurosciences, University of California, San Diego, La Jolla, USA), Shareefa Dalvie (Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa), Tânia K. de Araujo (Department of Medical Genetics, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, Brazil), Greig I. de Zubicaray (Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia), Sonja M.C. de Zwarte (Department of Psychiatry,

Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Anouk den Braber (Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Nhat Trung Doan (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Katharina Dohm (Department of Psychiatry, University of Münster, Münster, Germany), Stefan Ehrlich (Division of Psychological & Social Medicine and Developmental Neurosciences, Technische Universität Dresden, Dresden, Germany), Hannah-Ruth Engelbrecht (Division of Human Genetics, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa), Susanne Erk (Division of Mind and Brain Research, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany), Chun Chieh Fan (Department of Cognitive Science, University of California San Diego, San Diego, USA), Iryna O. Fedko (Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Sonya F. Foley (Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, UK), Judith M. Ford (San Francisco Veterans Administration Medical Center, San Francisco, USA), Masaki Fukunaga (Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan), Melanie E. Garrett (Duke Molecular Physiology Institute, Duke University Medical Center, Durham, USA), Tian Ge (Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA), Sudheer Giddaluru (NORMENT - K.G. Jebsen Centre for Psychosis Research, Department of Clinical Science, NORMENT University of Bergen, Bergeb, Norway), Aaron L. Goldman (Lieber Institute for Brain Development, Baltimore, USA), Nynke A. Groenewold (Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa), Dominik Grotegerd (Department of Psychiatry, University of Münster, Münster, Germany), Tiril P. Gurholt (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Boris A. Gutman (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Narelle K. Hansell (Queensland Brain Institute, University of Queensland, St Lucia, Australia), Mathew A. Harris (Centre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK), Marc B. Harrison (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Courtney C. Haswell (Duke UNC Brain Imaging and Analysis Center, Duke University Medical Center, Durham, USA), Michael Hauser (Duke Molecular Physiology Institute, Duke University Medical Center, Durham, USA), Stefan Herms (Department of Biomedicine, University of Basel, Basel, Switzerland), Dirk J. Heslenfeld (Department of Cognitive and Clinical Neuropsychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), New Fei Ho (Research Division, Institute of Mental Health, Singapore, Singapore), David Hoehn (Max Planck Institute of Psychiatry, Munich, Germany), Per Hoffmann (Department of Biomedicine, University of Basel, Basel, Switzerland), Laurena Holleran (Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway, Galway, Ireland), Martine Hoogman (Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), Jouke-Jan Hottenga (Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Masashi Ikeda (Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan), Deborah Janowitz (Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany), Iris E. Jansen (Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit

Amsterdam, Amsterdam, The Netherlands), Tianye Jia (Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China), Christiane Jockwitz (Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany), Ryota Kanai (Department of Neuroinformatics, Araya, Inc., Tokyo, Japan), Sherif Karama (Department of Psychiatry, McGill University, Montreal, Canada), Dalia Kasperaviciute (Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK), Tobias Kaufmann (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Sinead Kelly (Public Psychiatry Division, Massachusetts Mental Health Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA), Masataka Kikuchi (Department of Genome Informatics, Graduate School of Medicine, Osaka University, Suita, Japan), Marieke Klein (Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), Michael Knapp (Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany), Annchen R. Knodt (Department of Psychology and Neuroscience, Duke University, Durham, USA), Bernd Krämer (Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany), Max Lam (Research Division, Institute of Mental Health, Singapore, Singapore), Thomas M. Lancaster (Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, UK), Phil H. Lee (Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA), Tristram A. Lett (Division of Mind and Brain Research, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany), Lindsay B. Lewis (McGill Centre for Integrative Neuroscience, McGill University, Montreal, Canada), Iscia Lopes-Cendes (Department of Medical Genetics, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, Brazil), Michelle Luciano (Department of Psychology, University of Edinburgh, Edinburgh, UK), Fabio Macciardi (Department of Psychiatry and Human Behavior, School of Medicine , University of California, Irvine, Irvine, USA), Andre F. Marquand (Department of Cognitive Neuroscience, Radboud university medical center, Nijmegen, The Netherlands), Samuel R. Mathias (Department of Psychiatry, Yale University School of Medicine, New Haven, USA), Tracy R. Melzer (Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand), Yuri Milaneschi (Psychiatry, Amsterdam UMC Vrije Universiteit, Amsterdam, The Netherlands), Nazanin Mirza-Schreiber (Max Planck Institute of Psychiatry, Munich, Germany), Jose C.V. Moreira (BRAINN - Brazilian Institute of Neuroscience and Neurotechnology, Campinas, Brazil), Thomas W. Mühleisen (Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany), Bertram Müller-Myhsok (Max Planck Institute of Psychiatry, Munich, Germany), Pablo Najt (Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway, Galway, Ireland), Soichiro Nakahara (Department of Psychiatry and Human Behavior, School of Medicine University of California, University of California, Irvine, Irvine, USA), Kwangsik Nho (Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA), Loes M. Olde Loohuis (Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, USA), Dimitri Papadopoulos Orfanos (NeuroSpin, CEA, Université Paris-Saclay, Gif sur Yvette, France), John F. Pearson (Biostatistics and Computational Biology Unit, University of Otago, Christchurch, Christchurch, New Zealand), Toni L. Pitcher (Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand), Benno Pütz (Max Planck Institute of Psychiatry, Munich, Germany), Anjanibhargavi Ragothaman (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics

Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Faisal M. Rashid (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Ronny Redlich (Department of Psychiatry, University of Münster, Münster, Germany), Céline S. Reinbold (Department of Biomedicine, University of Basel, Basel, Switzerland), Jonathan Repple (Department of Psychiatry, University of Münster, Münster, Germany), Geneviève Richard (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Brandalyn C. Riedel (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Shannon L. Risacher (Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA), Cristiane S. Rocha (Department of Medical Genetics, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, Brazil), Nina Roth Mota (Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), Lauren Salminen (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Arvin Saremi (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Andrew J. Saykin (Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA), Fenja Schlag (Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands), Lianne Schmaal (Orygen, The National Centre of Excellence for Youth Mental Health, Melbourne, Australia), Peter R. Schofield (Neuroscience Research Australia, Sydney, Australia), Rodrigo Secolin (Department of Medical Genetics, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, Brazil), Chin Yang Shapland (Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands), Li Shen (Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, USA), Jean Shin (The Hospital for Sick Children, University of Toronto, Toronto, Canada), Elena Shumskaya (Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), Ida E. Sønderby (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Emma Sprooten (Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands), Lachlan T. Strike (Queensland Brain Institute, University of Queensland, St Lucia, Australia), Katherine E. Tansey (MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK), Alexander Teumer (Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany), Anbupalam Thalamuthu (Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia), Sophia I. Thomopoulos (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Diana Tordesillas-Gutiérrez (Neuroimaging Unit, Valdecilla Biomedical Research Institute IDIVAL, Santander, Spain), Jessica A. Turner (Department of Psychology, Georgia State University, Atlanta, USA), Anne Uhlmann (Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa), Costanza Ludovica Vallerga (Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia), Dennis van der Meer (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Marjolein M.J. van Donkelaar

(Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), Liza van Eijk (School of Psychology, University of Queensland, Brisbane, Australia), Theo G.M. van Erp (Department of Psychiatry and Human Behavior, School of Medicine University of California, University of California, Irvine, Irvine, USA), Neeltje E.M. van Haren (Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Daan van Rooij (Department of Cognitive Neuroscience, Radboud university medical center, Nijmegen, The Netherlands), Marie-José van Tol (Cognitive Neuroscience Center, Department of Neuroscience, University Medical Center Groningen, Groningen, The Netherlands), Jan H. Veldink (Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Ellen Verhoef (Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands), Esther Walton (Department of Psychology, Georgia State University, Atlanta, USA), Mingyuan Wang (Research Division, Institute of Mental Health, Singapore, Singapore), Yunpeng Wang (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Joanna M. Wardlaw (Centre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK), Wei Wen (Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia), Lars T. Westlye (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Christopher D. Whelan (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Stephanie H. Witt (Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany), Katharina Wittfeld (, German Center for Neurodegenerative Diseases Rostock/Greifswald, Greifswald, Germany), Christiane Wolf (Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany), Thomas Wolfers (Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), Clarissa L. Yasuda (Department of Neurology, FCM, University of Campinas - UNICAMP, Campinas, Brazil), Dario Zaremba (Department of Psychiatry, University of Münster, Münster, Germany), Zuo Zhang (Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK), Alyssa H. Zhu (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), Marcel P. Zwiers (Department of Cognitive Neuroscience, Radboud university medical center, Nijmegen, The Netherlands), Eric Artiges (INSERM Unit 1000 - Neuroimaging & Psychiatry, Paris Saclay University, Gif sur Yvette, France), Amelia A. Assareh (Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia), Rosa Ayesa-Arriola (Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Santander, Spain), Aysenil Belger (Duke UNC Brain Imaging and Analysis Center, Duke University Medical Center, Durham, USA), Christine L. Brandt (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Gregory G. Brown (Department of Psychiatry, University of California San Diego, San Diego, USA), Sven Cichon (Department of Biomedicine, University of Basel, Basel, Switzerland), Joanne E. Curran (Department of Human Genetics and South Texas Diabetes and Obesity Institute, Rio Grande Valley School of Medicine, University of Texas, Brownsville, USA), Gareth E. Davies (Avera Institute for Human Genetics, Sioux Falls, USA), Franziska Degenhardt (Institute of Human Genetics, School of

Medicine & University Hospital Bonn, University of Bonn, Bonn, Germany), Bruno Dietsche (Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany), Srdjan Djurovic (Department of Medical Genetics, Oslo University Hospital, Oslo, Norway), Colin P. Doherty (Department of Neurology, St James's Hospital, Dublin, Ireland), Ryan Espiritu (Information Sciences Institute, University of Southern California, Los Angeles, USA), Daniel Garijo (Information Sciences Institute, University of Southern California, Los Angeles, USA), Yolanda Gil (Information Sciences Institute, University of Southern California, Los Angeles, USA), Penny A. Gowland (Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK), Robert C. Green (, Brigham and Women's Hospital, Boston, USA), Alexander N. Häusler (Center for Economics and Neuroscience, University of Bonn, Bonn, Germany), Walter Heindel (Department of Clinical Radiology, University of Münster, Münster, Germany), Beng-Choon Ho (Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA), Wolfgang U. Hoffmann (Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany), Florian Holsboer (HMNC Holding GmbH, Munich, Germany), Georg Homuth (Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany), Norbert Hosten (Institute of Diagnostic Radiology and Neuroradiology, University Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany), Clifford R. Jack Jr. (Dept of Radiology, Mayo Clinic, Rochester, USA), MiHyun Jang (Information Sciences Institute, University of Southern California, Los Angeles, USA), Andreas Jansen (Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany), Knut Kolskår (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Sanne Koops (Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Axel Krug (Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany), Kelvin O. Lim (Department of Psychiatry, University of Minnesota, Minneapolis, USA), Jurjen J. Luykx (Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Daniel H. Mathalon (Department of Psychiatry and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, USA), Karen A. Mather (Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia), Venkata S. Mattay (Lieber Institute for Brain Development, Baltimore, USA), Sarah Matthews (MRC Integrative Epidemiology Unit, Department of Population Health Sciences, Bristol Medical School, Bristol, UK), Jaqueline Mayoral Van Son (Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Santander, Spain), Sarah C. McEwen (Department of Psychiatry, University of California San Diego, La Jolla, USA), Ingrid Melle (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Derek W. Morris (Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway, Galway, Ireland), Bryon A. Mueller (Department of Psychiatry, University of Minnesota, Minneapolis, USA), Matthias Nauck (Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany), Jan E. Nordvik (Sunnaas Rehabilitation Hospital HT, Nesodden, Norway), Markus M. Nöthen (Institute of Human Genetics, School of Medicine & University Hospital Bonn, University of Bonn, Bonn, Germany), Daniel S. O'Leary (Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA), Nils Opel (Department of Psychiatry, University of Münster, Münster, Germany), Marie - Laure Paillère Martinot (INSERM Unit 1000 - Neuroimaging & Psychiatry, Paris Saclay University, Gif sur Yvette, France), G. Bruce

Pike (Radiology and Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada), Adrian Preda (School of Medicine, University of California Irvine, Irvine, USA), Erin B. Quinlan (Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK), Varun Ratnakar (Information Sciences Institute, University of Southern California, Los Angeles, USA), Simone Reppermund (Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia), Vidar M. Steen (NORMENT - K.G. Jebsen Centre for Psychosis Research, Department of Clinical Science, NORMENT University of Bergen, Bergen, Norway), Fábio R. Torres (Department of Medical Genetics, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, Brazil), Dick J. Veltman (Psychiatry, Amsterdam UMC Vrije Universiteit, Amsterdam, The Netherlands), James T. Voyvodic (Duke UNC Brain Imaging and Analysis Center, Duke University Medical Center, Durham, USA), Robert Whelan (School of Psychology, Trinity College Dublin, Dublin, Ireland), Tonya White (Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands), Hidenaga Yamamori (Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan), Marina K.M. Alvim (Department of Neurology, FCM, University of Campinas - UNICAMP, Campinas, Brazil), David Ames (Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Australia), Tim J. Anderson (Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand), Ole A. Andreassen (NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, NORMENT Oslo University Hospital, Oslo, Norway), Alejandro Arias-Vasquez (Department of Psychiatry, Radboud university medical center, Nijmegen, The Netherlands), Mark E. Bastin (Centre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK), Bernhard T. Baune (Department of Psychiatry, The University of Melbourne, Melbourne, Australia.), John Blangero (Department of Human Genetics and South Texas Diabetes and Obesity Institute, Rio Grande Valley School of Medicine, University of Texas, Brownsville, USA), Dorret I. Boomsma (Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Henry Brodaty (Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia), Han G. Brunner (Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), Randy L. Buckner (Department of Psychology and Center for Brain Science, Harvard University, Boston, USA), Jan K. Buitelaar (Department of Cognitive Neuroscience, Radboud university medical center, Nijmegen, The Netherlands), Juan R. Bustillo (Department of Psychiatry, University of New Mexico, Albuquerque, USA), Wiepke Cahn (Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Vince Calhoun (Department of Electrical and Computer Engineering, The University of New Mexico, Albuquerque, USA), Xavier Caseras (MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK), Svenja Caspers (Institute for Anatomy I Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany), Gianpiero L. Cavalleri (Molecular and Cellular Therapeutics, The Royal College of Surgeons In Ireland, Dublin, Ireland), Fernando Cendes (Department of Neurology, FCM, University of Campinas - UNICAMP, Campinas, Brazil), Aiden Corvin (Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland), Benedicto Crespo-Facorro (Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria-IDIVAL, Santander, Spain), John C. Dalrymple-Alford (Department of Psychology, University of Canterbury, Christchurch, New Zealand), Udo Dannlowski (Department of Psychiatry, University of Münster, Münster, Germany), Eco J.C. de Geus (Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Ian J. Deary (Centre for

Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK), Norman Delanty (FutureNeuro Research Centre , Royal College of Surgeons in Ireland, Dublin, Ireland), Chantal Depondt (Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium), Sylvane Desrivières (Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK), Gary Donohoe (Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway, Galway, Ireland), Thomas Espeseth (Department of Psychology, University of Oslo, Oslo, Norway), Guillén Fernández (Department of Cognitive Neuroscience, Radboud university medical center, Nijmegen, The Netherlands), Simon E. Fisher (Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands), Herta Flor (Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany), Andreas J. Forstner (Institute of Human Genetics, School of Medicine & University Hospital Bonn, University of Bonn, Bonn, Germany), Clyde Francks (Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands), Barbara Franke (Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands), David C. Glahn (Department of Psychiatry, Yale University School of Medicine, New Haven, USA), Randy L. Gollub (Department of Psychiatry, Massachusetts General Hospital, Boston, USA), Hans J. Grabe (German Center for Neurodegenerative Diseases Rostock/Greifswald, Greifswald, Germany), Oliver Gruber (Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany), Asta K. Håberg (Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway), Ahmad R. Hariri (Department of Psychology and Neuroscience, Duke University, Durham, USA), Catharina A. Hartman (Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Ryota Hashimoto (Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Japan), Andreas Heinz (Division of Mind and Brain Research, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany), Manon H.J. Hillegers (Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands), Pieter J. Hoekstra (Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands), Avram J. Holmes (Department of Psychology, Yale University, New Haven, USA), L. Elliot Hong (Department of Psychiatry, Maryland Psychiatry Research Center, University of Maryland School of Medicine, Baltimore, USA), William D. Hopkins (Neuroscience Institute, Georgia State University, Atlanta, USA), Hilleke E. Hulshoff Pol (Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands), Terry L. Jernigan (Center for Human Development, University of California San Diego, La Jolla, USA), Erik G. Jönsson (Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden), René S. Kahn (Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA), Martin A. Kennedy (Department of Pathology and Biomedical Science, University of Otago, Christchurch, Christchurch, New Zealand), Tilo T.J. Kircher (Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany), Peter Kochunov (Department of Psychiatry, Maryland Psychiatry Research Center, University of Maryland School of Medicine, Baltimore, USA), John B.J . Kwok (Neurogenetics and Epigenetics, Brain and Mind Centre, The University of Sydney, Sydney, Australia), Stephanie Le Hellard (NORMENT - K.G. Jebsen Centre for Psychosis Research,

Department of Clinical Science, NORMENT University of Bergen, Bergen, Norway), Nicholas G. Martin (Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia), Jean - Luc Martinot (INSERM Unit 1000 - Neuroimaging & Psychiatry, Paris Saclay University, Gif sur Yvette, France), Colm McDonald (Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway, Galway, Ireland), Katie L. McMahon (Herston Imaging Research Facility, School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia), Andreas Meyer-Lindenberg (Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany), Rajendra A. Morey (Duke UNC Brain Imaging and Analysis Center, Duke University Medical Center, Durham, USA), Lars Nyberg (Department of Integrative Medical Biology, Umeå University, Umeå, Sweden), Jaap Oosterlaan (Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands), Roel A. Ophoff (Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, USA), Tomáš Paus (Bloorview Research Institute, University of Toronto, Toronto, Canada), Zdenka Pausova (The Hospital for Sick Children, University of Toronto, Toronto, Canada), Brenda W.J.H. Penninx (Psychiatry, Amsterdam UMC Vrije Universiteit, Amsterdam, The Netherlands), Tinca J.C. Polderman (Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Danielle Posthuma (Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Marcella Rietschel (Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany), Joshua L. Roffman (Department of Psychiatry, Massachusetts General Hospital, Boston, USA), Laura M. Rowland (Department of Psychiatry, Maryland Psychiatry Research Center, University of Maryland School of Medicine, Baltimore, USA), Perminder S. Sachdev (Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia), Philipp G. Sämann (Max Planck Institute of Psychiatry, Munich, Germany), Gunter Schumann (Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK), Kang Sim (General Psychiatry, Institute of Mental Health, Singapore, Singapore), Sanjay M. Sisodiya (Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK), Jordan W. Smoller (Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA), Iris E. Sommer (Department of Medical and Biological Psychology, University of Bergen, Bergen, Norway), Beate St Pourcain (MRC Integrative Epidemiology Unit, Department of Population Health Sciences, Bristol Medical School, Bristol, UK), Dan J. Stein (Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa), Arthur W. Toga (Laboratory of Neuro Imaging, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, USA), Julian N. Trollor (Department of Developmental Disability Neuropsychiatry, University of New South Wales, Sydney, Australia), Nic J.A. Van der Wee (Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands), Dennis van 't Ent (Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands), Henry Völzke (Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany), Henrik Walter (Division of Mind and Brain Research, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany), Bernd Weber (Institute of Experimental Epileptology and Cognition Research, University Hospital Bonn, Bonn, Germany), Daniel R. Weinberger (Lieber Institute for Brain Development, Baltimore, USA), Margaret J. Wright (Queensland Brain Institute, University of Queensland, St Lucia, Australia), Juan

Zhou (Center for Cognitive Neuroscience, Neuroscience and behavioral disorders program, Duke-National University of Singapore Medical School, Singapore, Singapore), Jason L. Stein (Department of Genetics & UNC Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, USA), Paul M. Thompson (Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA), and Sarah E. Medland (Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia).